Regeneron's Phase 3 study for suptavumab fails to meet objectives

The study hoped to show the drug could prevent medically attended RSV infections in infants.
The study hoped to show the drug could prevent medically attended RSV infections in infants. | File photo

Regeneron Pharmaceuticals Inc. recently announced that a Phase 3 study evaluating suptavumab (REGN2222), an antibody to respiratory syncytial virus (RSV), failed to meet its primary endpoint.

The study hoped to show the drug could prevent medically attended RSV infections in infants. According to Regeneron, suptavumab did show signs of efficacy in a subgroup of patients. The company noted suptavumab’s adverse effects were generally on par with the placebo. Regeneron will discontinue additional clinical development options for the antibody.

"We are disappointed in these results, as we had hoped suptavumab might offer a new option for the thousands of infants impacted by serious RSV infections every year," Dr. George Yancopoulos, president and chief scientific officer of Regeneron, said in a statement. "Regeneron has a robust pipeline across many serious diseases, and we look forward to important data readouts from other programs in the coming weeks and months."

Regeneron, a leading biotechnology company, focuses on the invention of medicines that fight serious diseases. The company was founded 30 years ago by physician-scientists and has created six FDA-approved treatments and around a dozen additional product candidates.

Want to get notified whenever we write about Regeneron Pharmaceuticals, Inc. ?
Next time we write about Regeneron Pharmaceuticals, Inc., we'll email you a link to the story. You may edit your settings or unsubscribe at any time.
Organizations in this story

Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Rd Tarrytown, NY - 10591